High-Throughput Screen Identifies Cyclic Nucleotide Analogs That Inhibit Prostatic Acid Phosphatase by McCoy, Eric S. et al.
High throughput screen identifies cyclic nucleotide analogs that
inhibit Prostatic acid phosphatase
Eric S. McCoy1,*, Wendy A. Lea2,*, Bryan T. Mott2, David J. Maloney2, Ajit Jadhav2, Anton
Simeonov2,3, and Mark J. Zylka1,3
1Department of Cell and Molecular Physiology, UNC Neuroscience Center, University of North
Carolina, CB #7545, Chapel Hill, North Carolina 27599
2NIH Chemical Genomics Center, National Human Genome Research Institute, National
Institutes of Health, Bethesda, MD
Abstract
The secretory and transmembrane isoforms of Prostatic acid phosphatase (PAP) can
dephosphorylate extracellular adenosine 5′-monophosphate (AMP) to adenosine, classifying PAP
as an ectonucleotidase. Currently, there are no compounds that inhibit PAP in living cells. To
identify small molecule modulators of PAP, we used a 1,536-well based quantitative high-
throughput fluorogenic assay to screen the Library of Pharmacologically Active Compounds
(LOPAC1280) arrayed as eight-concentration dilution series. This fluorogenic assay used
difluoro-4-methylumbelliferyl phosphate (DiFMUP) as substrate and collected data in kinetic
mode. Candidate hits were subsequently tested in an orthogonal absorbance-based biochemical
assay that used AMP as substrate. From these initial screens, three inhibitors of secretory human
(h) and mouse (m)PAP were identified: 8-(4-chlorophenylthio) cAMP (pCPT-cAMP),
calmidazolium chloride and nalidixic acid. These compounds did not inhibit recombinant alkaline
phosphatase. Of these compounds, only pCPT-cAMP and a related cyclic nucleotide analog [8-(4-
chlorophenylthio) cGMP; pCPT-cGMP] inhibited the ectonucleotidase activity of transmembrane
PAP in a cell-based assay. These cyclic nucleotides are structurally similar to AMP but cannot be
hydrolyzed by PAP. In summary, we identified two cyclic nucleotide analogs that inhibit secretory
and transmembrane PAP in vitro and in live cells.
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Introduction
Prostatic acid phosphatase (PAP, also known as ACPP) has been used for over 50 years as a
prostate cancer biomarker.1 Recently, we found that the transmembrane isoform of PAP was
expressed in nociceptive (pain-sensing) dorsal root ganglia neurons.2 In addition, we found
that the secretory and transmembrane isoforms of PAP have ectonucleotidase activity, as
demonstrated by the ability of each isoform to dephosphorylate extracellular AMP to
adenosine. In mice, intrathecal injection of the secretory isoform of PAP has antinociceptive
effects in chronic inflammatory and neuropathic pain models that persist for three days.2
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These antinociceptive effects were entirely dependent on adenosine A1 receptor activation,
suggesting PAP generates adenosine in vivo.
Intrathecal injections are routinely performed in humans but they are invasive. Moreover, it
is impractical to deliver PAP protein orally because, like all proteins, PAP is susceptible to
proteolysis in the digestive tract. In contrast, small molecule activators of PAP could
enhance the activity of endogenously expressed PAP and be made orally bioavailable. At
present, there are no known small molecule activators of PAP.
Conversely, it would be advantageous to have small molecules that selectively and acutely
inhibit PAP for physiological studies. L-(+)-tartrate is the most commonly used inhibitor of
PAP but must be used at high (mM) concentrations. Also, L-(+)-tartrate inhibits other acid
phosphatases.3 α-Benzylaminobenzylphosphonic acid (BABPA), a derivative of
benzylphosphonic acid, was found to inhibit PAP in the low nanomolar range.4 While
potent, this inhibitor is not routinely used because it is difficult to obtain (not commercially
available and must be synthesized). It is unknown if BABPA inhibits other phosphatases.
Discovering selective PAP inhibitors would provide a way to examine the acute biological
effects of PAP inhibition and could complement studies with Pap−/− mice where enzyme
activity is eliminated throughout life.2
We previously identified several structurally diverse inhibitors of hPAP using a high-
throughput 384-well single point fluorogenic screen.5 Here, we modified this single-point
assay so that we could perform a quantitative (multi-concentration) high-throughput screen
in 1,536 well plates with secretory hPAP and DiFMUP as substrate. Quantitative HTS has
several advantages over traditional single point screens, including fewer false negatives and
generation of dose-response curves as part of the screen.6 We screened the Library of
Pharmacologically Active Compounds (LOPAC1280) as an eight-point dilution series and
identified several potential hPAP inhibitors. Three of these compounds also inhibited hPAP
and recombinant mPAP in an orthogonal biochemical assay. This orthogonal assay used
AMP, a physiologically-relevant PAP substrate. Of these compounds, pCPT-cAMP and a
related analog (pCPT-cGMP) were the only compounds that inhibited PAP in a real-time
cell-based calcium mobilization assay. These cyclic nucleotide analogs are the first known
compounds that inhibit PAP in vitro as well as in living cells.
Materials and Methods
Reagents
Most reagents were purchased from Sigma-Aldrich (St. Louis, MO), including HEPES,
DMSO, sodium citrate, malachite green oxalate, sodium molybdate, sodium L-(+)tartrate,
sodium orthovanadate, sodium fluoride, EDTA, HCl, AMP, Triton X-100, Tween-20,
purified human PAP (hPAP; #P1774), recombinant bovine alkaline phosphatase (ALP;
#P8361) and human Protein Tyrosine Phosphatase-1B (PTP; #P6244). DiFMUP was
obtained from Invitrogen (Carlsbad, CA), and potato acid phosphatase (pAP) was obtained
from Roche Applied Science (Indianapolis, IN). Recombinant mouse PAP (mPAP) was
generated as described previously.7 Medium binding black solid-bottom 1,536-well plates
were obtained from Greiner Bio One (Monroe, NC) and were used for the LOPAC screen.
Black clear-bottom 96-well plates that were used to measure hydrolysis of AMP were
purchased from Corning Incorporated (Corning, NY). The buffer used for hPAP and mPAP
fluorogenic assays was 50 mM HEPES, pH 7.0, 1 mM EDTA and 0.01% Tween-20. A
buffer consisting of 50 mM sodium acetate, pH 5.3, 0.01% Tween-20 was used for the pAP
fluorogenic assay, while ALP was assayed in 50 mM Tris-HCl, pH 8.0, 0.01% Tween-20.
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The LOPAC1280 library and dry powder versions of the selected hit compounds identified
from the LOPAC1280 screen were obtained from Sigma-Aldrich. The LOPAC1280 library
compounds were arrayed as inter-plate dilution series starting from 10 mM stock in DMSO
as described elsewhere.8 6-hydroxy-5-nitro-2-[(E)-2-(2-propoxy-naphthalen-1-yl)-
vinyl]-3H-pyrimidin-4-one (Asinex 49) was purchased from Asinex Corporation (BAS
08865249; Moscow, Russia).
BABPA was synthesized based on a published procedure.4 Briefly, to a stirring solution of
E-N-benzylidene-1-phenylmethanamine (0.5 g, 2.56 mmol) at 0°C was added triethyl
phosphite (0.448 g, 2.56 mmol). The reaction mixture was heated to 70°C for 12 h, upon
which time any excess triethyl phosphite was removed under reduced pressure. The
remaining residue was purified directly on silica. Gradient elution (40–70% ethyl acetate in
hexanes) afforded the desired product as a colorless, viscous oil: yield (554 mg, 1.66 mmol,
65%).
To a stirring solution of diethyl (benzylaminophenyl) methyl phosphonate (0.13 g, 0.39
mmol) in water was added hydrochloric acid (1 mL, 10 mmol). The reaction mixture was
heated to 50°C for 4 h. Upon completion, the reaction mixture was carefully neutralized
with sat. aq. sodium bicarbonate. The solution was filtered and purified directly by reverse
phase chromatography. Gradient elution (10–60% acetonitrile in water) and subsequent
lyophilization of the appropriate fractions afforded the desired product as a colorless,
powdery solid: yield (0.027 g, 0.098 mmol, 25%).
Quantitative HTS assay protocol and HTS data analysis
To conduct the primary screen against the LOPAC library, three μL of enzyme (final
concentration: 2 nM for hPAP) in columns 1, 2, 5–48 and three μL of the assay buffer in
columns 3, 4 were dispensed into 1,536-well Greiner black assay plates. Compounds (23
nL) were transferred via Kalypsys pintool equipped with 1,536-pin array (10 nL slotted pins,
V&P Scientific, San Diego, CA), with the LOPAC compounds pin-transferred into columns
5–48 and the control compound, BABPA, pin-transferred into column 2. The plates were
incubated for 15 min at room temperature before the addition of 1 μL fluorogenic substrate
DiFMUP (final concentration 100 μM). Throughout the screen, all reagent bottles were kept
at 4°C to minimize degradation. Immediately following substrate addition, fluorescence data
were collected on a ViewLux high-throughput imager (PerkinElmer, Waltham, MA) every
min for 3 min using standard UV excitation filter (340 nm, bandwidth 60 nm) and the
umbelliferone emission filter of 450 nm (bandwidth 20 nm); the change in fluorescence,
measured for every sample over the three-minute initial reaction time course, was used to
calculate the Z′ statistical parameter using the formula in Zhang et al.,9 as well as for
calculation of normalized responses. Data were normalized against no-enzyme wells
(columns 3, 4) and enzyme-containing wells (column 1) and were further fitted using a four-
parameter Hill equation through publicly-available curve-fitting algorithms (http://
ncgc.nih.gov/pub/openhts/), as described in detail elsewhere.6, 8
For follow-up fluorogenic assays against mPAP and additional phosphatases, the protocols
were the same as described above with the exception that the compounds were arrayed as
12-point dose responses within each plate. Final concentrations of the phosphatases used in
the profiling were as follows: 1.8 nM for mPAP, 1.5 nM for pAP and 5 pM for ALP. The
data were normalized against enzyme-containing and no-enzyme controls, and data were
fitted using a sigmoidal dose-response regression algorithm in GraphPad Prism (La Jolla,
CA).
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AMP hydrolysis enzyme assay
Enzyme assays were performed as previously described.7 Briefly, enzyme (1 U hPAP, 1 U
mPAP or 100 U ALP) was added to reaction mixture (50 μL total volume) in a 1.5 mL
microcentrifuge tube containing 400 μM, 1 mM, or 100 μM AMP corresponding to the KM
of hPAP, mPAP and ALP for AMP, respectively, 50 mM HEPES buffer pH 7.0 and test
compound (10−4 to 10−7 M). Compounds were pre-incubated with enzyme for 3 min at 37°C
prior to the addition of 950 μL malachite green color reagent (0.03% (w/v) malachite green
oxalate, 0.2% (w/v) sodium molybdate, 0.05% (v/v) Triton X-100 in 0.7 M HCl). Reactions
were incubated at room temperature for 30 min, and the colorimetric reaction was quenched
with 22.4 μL of 38% sodium citrate. The samples (100 μL) were transferred to a 96-well
black, clear-bottom plate (Corning), and inorganic phosphate release was quantified at 650
nm on a SpectraMax Plus plate reader (Molecular Devices, Sunnyvale, CA). Negative
controls contained AMP, buffer and no enzyme. For each compound tested, negative
controls also contained the same concentration of compound as being tested. The absorbance
measurements in the no enzyme control were subtracted from the absorbance measurements
for each test sample. The raw absorbance data was converted to nmol of phosphate released
per minute using an inorganic phosphate standard curve (KH2PO4). Data were analyzed
using EXCEL, and the dose response data were fit by non-linear regression equation using
GraphPad Prism 5.
Calcium Mobilization Assay
Calcium imaging was performed as described previously.10 Briefly, HEK293 cells were
plated at 2×106 per glass bottom MatTek dish (MatTek, Ashland, MA). Prior to plating,
each dish was coated with 0.1 μg/mL poly-D-lysine (Sigma). After 24 h, cells were
transfected using lipofectamine (Invitrogen) per manufacturer’s instructions. Control
experiments contained pcDNA3.1/chimeric Gαq-s5 protein/pcDNA3.1/Venus
(0.3/0.3/0.3/0.1 μg DNA ratio). Experimental conditions utilized A2B/chimeric Gαq-s5
protein/pcDNA3.1 or transmembrane PAP/Venus. The following day, cells were washed 3×
with HBSS (Gibco) loaded with 2 μM Fura-2AM (Invitrogen) in HBSS for 1 h at room
temperature in the dark and were washed 3× with HBSS and incubated for 30 min prior to
imaging. Cells were preincubated with each compound in HBSS for 1 h and for 5 min with
10 μM αβ-methylene ADP in HBSS to inhibit endogenous ecto-5′-nucleotidase. A 30 s
baseline was obtained followed by 2 min of agonist in the presence of 10 μM αβ-methylene
ADP. Cells were imaged on a Nikon Ti-E (Nikon; Melville, NY) and analyzed using NIS
Elements Imaging software. Data were exported to EXCEL to create graphs and GraphPad
Prism 5 to analyze area under curve. Area under curve was obtained for 1 min post agonist.
Results and Discussion
BABPA inhibits mouse and human secretory PAP
BABPA inhibits PAP with nanomolar efficacy.4 As a positive control, we confirmed that
BABPA inhibited hPAP (IC50 = 4.97 nM) in our fluorgenic assay (Fig 1A). In addition,
BABPA inhibited mPAP (IC50 = 20.6 nM) but not pAP or ALP (Fig 1A). Taken together,
these data indicate BABPA is relatively selective for mammalian PAP.
Quantitative high-throughput screening of the LOPAC1280 Library
We next used quantitative high-throughput screening to identify candidate PAP inhibitors in
the LOPAC1280 library.6 This entailed testing the library compounds in a dose-response
format, with eight concentrations ranging from 0.3 nM to 115 μM. The mean Z′ value9 was
~0.9 across all plates, indicating a stable assay performance. After screening the library, the
compounds were categorized into four groups: inactive, false positives, potential inhibitors,
and potential activators (Fig 1B). The groups were based on the shape and quality of the
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dose-response curves obtained (IC50, presence of two asymptotes, partial versus complete
curve). Autofluorescent hits were excluded when the starting fluorescence intensity in the
kinetic fluorogenic assay was greater than that of the uninhibited enzyme control. Based on
these results, a set of 13 compounds, comprised of 8 potential inhibitors (Fig 1C–J, Table 1)
and 5 potential activators, was selected for confirmatory testing and selectivity profiling
against mammalian and non-mammalian phosphatases.
Of the eight potential inhibitors, pCPT-cAMP, calmidazolium chloride and nalidixic acid
also inhibited mPAP but not pAP or ALP using the fluorogenic substrate (Table 1). While
all five activators enhanced the activity of hPAP in our initial screen and in confirmatory
fluorogenic assays, none activated hPAP in our orthogonal AMP hydrolysis assay (described
below) and hence were not studied further.
Confirmation of PAP inhibitors using an orthogonal 5′-AMP hydrolysis assay
To independently validate hits and determine if any were false positives (i.e., non-specific
compound interactions with the DiFMUP substrate or quenching), we employed an
orthogonal non-fluorescence-based enzyme assay that utilized AMP, an endogenous PAP
substrate.7 For each reaction, hydrolysis of AMP by hPAP was measured in the presence of
the eight inhibitors described above (at increasing doses), while the substrate concentration
was held constant at a value close to the reported KM for each enzyme [hPAP – 400 μM
AMP (KM = 0.3–2 mM), mPAP – 1 mM AMP (KM = 0.9–1.6 mM), ALP – 100 μM AMP
(KM = 0.018–15.4 mM)].11, 12 Of these eight compounds, calmidazolium chloride, pCPT-
cAMP, nalidixic acid and lonidamine inhibited hPAP and mPAP in the low micromolar
range (Table 1; Fig 2A–D; calculated IC50 values and structures are inset).
In addition, we tested “Compound 49” [6-hydroxy-5-nitro-2-[(E)-2-(2-propoxy-
naphthalen-1-yl)-vinyl]-3H-pyrimidin-4-one], a low micromolar hPAP inhibitor previously
identified in a fluorogenic-based screen.5 Compound 49 inhibited AMP hydrolysis by hPAP
and mPAP with an IC50 of 2.90 μM for hPAP and 42.9 μM for mPAP (Fig 2E) but did not
inhibit ALP (Fig 2F). As a second inhibitor control, we used L-(+)-tartrate (10 mM), which
has a low affinity for PAP and must be used at high concentrations to inhibit PAP enzymatic
activity.3 L-(+)-tartrate inhibited hPAP and mPAP in our 5′-AMP hydrolysis assay but did
not inhibit ALP (Fig 2F).
Transmembrane PAP ectonucleotidase activity was inhibited in a real-time cell-based
assay
We recently developed a real-time, cell-based calcium mobilization assay to study the
hydrolysis of AMP to adenosine by transmembrane PAP.10 This assay is based on our
observation that the A2B adenosine receptor can be activated by adenosine but not AMP.
HEK293 cells were transiently transfected with the A2B adenosine receptor and the chimeric
G protein subunit (Gq-s5), which couples the A2B adenosine receptor to calcium mobilization
(visualized with Fura-2AM). Transmembrane PAP was also transfected in some conditions
(Fig 3). Hydrolysis of AMP to adenosine was measured ± inhibitors, as read out by an
increase in calcium mobilization. A dose response was generated for BABPA (Fig 3A) and
pCPT-cAMP (Fig 3B). BABPA (5 μM) and pCPT-cAMP (100 μM) did not block activation
of the A2B receptor (using adenosine as ligand) but dose-dependently inhibited hydrolysis of
AMP to adenosine by transmembrane PAP (Fig 3A,B). In contrast, nalidixic acid blocked
A2B receptor activation by adenosine (data not shown), which precluded us from studying
nalidixic acid in this cell-based assay. Additionally, we were unable to study calmidazolium
chloride and lonidamine in this cell-based assay because both compounds killed the cells.
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Given that pCPT-cAMP was the only compound that inhibited human and mouse PAP in
vitro and in cells, we next tested a related cyclic nucleotide analog, 8-(4-chlorophenylthio)
cGMP (pCPT-cGMP). We found that pCPT-cGMP also inhibited transmembrane PAP in
the cell-based calcium mobilization assay (Fig 3C). In addition, pCPT-cGMP inhibited
human and mouse secretory PAP in vitro using AMP as substrate (Fig 3D) and using the
fluorogenic substrate (IC50=31.1 μM, IC50=49.7 μM, respectively). Neither pCPT-cAMP
nor pCPT-cGMP inhibited pAP, ALP or PTP using the fluorogenic substrate (data not
shown).
In this study, we used a fluorogenic assay that was capable of identifying small molecule
activators and inhibitors of PAP. PAP functions as an ectonucleotidase in nociceptive
neurons.2 Small molecule activators and inhibitors could be used to study the acute effects
of modulating PAP activity on nucleotide levels and adenosine production. After screening
1,280 small molecules contained within the LOPAC1280 collection, we identified 8
candidate inhibitors and 5 candidate activators. None of the activators identified from the
primary screen enhanced PAP in an orthogonal AMP hydrolysis assay, suggesting these
activators were false positives. We were similarly unable to identify hPAP activators in an
end-point screen of 28,800 small molecules.5 These results suggest that the odds of
identifying hPAP activators are extremely low. In contrast, three of the candidate inhibitors
(pCPT-cAMP, calmidazolium chloride, and nalidixic acid) identified in our present screen
selectively inhibited hPAP and mPAP (but not pAP or ALP) in an orthogonal AMP
hydrolysis assay. Of these three inhibitors, pCPT-cAMP was the only compound that
inhibited PAP in live cells.
pCPT-cAMP is commonly used as a membrane-permeant activator of cAMP- and cGMP-
dependent protein kinases and EPAC proteins, a class of cytoplasmic cAMP-dependent
guanine-nucleotide-exchange factors. pCPT-cAMP is structurally similar to AMP, a
physiologically-relevant substrate of PAP. While pCPT-cAMP is reportedly used to
modulate intracellular signaling, our findings suggest pCPT-cAMP acts extracellularly to
inhibit adenosine production in cells and tissues that express PAP. In fact, pCPT-cAMP is
charged at physiological pH, raising the issue of how this compound enters cells. Our cell-
based experiment indicates that pCPT-cAMP inhibits an extracellularly active enzyme
(which is coupled to extracellular activation of a cell surface receptor), strongly arguing for
an extracellular site of action. Additionally, Waidmann and colleagues found that pCPT-
cAMP blocked equilibrative nucleoside transporter 1 (ENT1).13 Inhibition of this adenosine
transporter elevated extracellular adenosine and activated adenosine A2A receptors in PC12
cells.13
While pCPT-cAMP effectively inhibited PAP, cAMP did not inhibit hPAP in the
fluorogenic assay (data not shown). One explanation for why pCPT-cAMP but not cAMP
inhibited PAP could be associated with the structural modification at the C8 position of the
purine ring (chlorophenylthio group). Similarly, the related cyclic nucleotide analog pCPT-
cGMP, which also contains the chlorophenylthio group at the C8 position, inhibited PAP in
vitro and extracellularly in cells. Thus, the C8 modification may be necessary to inhibit PAP
function. Intriguingly, these cyclic nucleotide analogs are structurally similar to AMP, the
natural substrate of PAP,2 but cannot be hydrolyzed to inorganic phosphate by PAP (Fig 2B,
3D).
Nalidixic acid, calmidazolium chloride and lonidamine inhibited PAP in biochemical assays;
however, we were unable to assess the inhibitory activity of these compounds in cells
because of off-target effects (nalidixic acid inhibited A2B while lonidamine and
calmidazolium chloride killed cells). These compounds are thus not likely to be useful for
inhibiting PAP in a more physiologically relevant setting, such as in live cells or in animals.
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Lastly, high throughput screens were used to identify inhibitors for tissue nonspecific
alkaline phosphatase.14 Alkaline phosphatases and PAP have ectonucleotidase activity and
utilize AMP as a substrate.15 Given that pCPT-cAMP inhibited PAP but not ALP, pCPT-
cAMP may prove useful for selectively inhibiting PAP in future physiological studies.
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Figure 1. Primary screen to identify PAP inhibitors
(A) BABPA inhibits mouse and human secretory PAP. Dose response curves were
generated for BABPA (see inset for structure) with hPAP (square), mPAP (triangle), pAP
(inverted triangle), and ALP (diamond) using the miniaturized fluorogenic assay. BABPA
inhibited hPAP (IC50 = 4.97 nM) and mPAP (IC50 = 20.6 nM). (B) Cumulative results of the
screen: compounds were categorized as autofluorescent false inhibitor compounds (blue),
potential inhibitors (cyan), potential activators (red), and inactives (black). BABPA control
(green) was added as a dilution series within each screening plate. Dose response curves are
shown for the 8 inhibitors detected in the primary screen: (C) 96, (D) 70, (E) 17, (F) 97, (G)
77, (H) 9, (I) 21, and (J) 29.
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Figure 2. Dose response curves for screen-identified inhibitors in an orthogonal 5′-AMP
hydrolysis assay
(A) Calmidazolium chloride [29], (B) pCPT-cAMP [21], (C) lonidamine [9], (D) nalidixic
acid [77], and (E) Asinex 49 dose-dependently inhibit 5′-AMP (0.4 mM and 1 mM)
hydrolysis by hPAP (black) and mPAP (red), respectively, at pH 7.0. Inorganic phosphate
was detected using malachite green. The structure and IC50 of each compound is shown
(insets). (F) Normalized inhibition observed for each compound at 100 μM towards hPAP,
mPAP and ALP with the exception of L-(+)-tartrate, which was used at 10 mM. CP-55940
[96], quercetin [70], 1-(4-chlorobenzyl)-5-methoxy-2-methylindole-3-acetic acid) [17], and
myricetin [97] did not inhibit mPAP. Data were normalized to enzyme control minus
inhibitor and analyzed using Student’s t-test *p<0.05; †p<0.01; ‡p<0.001.
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Figure 3. Dose responses for BABPA, pCPT-cAMP and pCPT-cGMP in a cell-based calcium
mobilization assay
(A) BABPA, (B) pCPT-cAMP [21], and (C) pCPT-cGMP dose-dependently inhibited
transmembrane PAP-mediated hydrolysis of 5′-AMP in a calcium mobilization assay.
Calcium mobilization in HEK293 cells expressing hA2B + Gαq-s5 ± transmembrane PAP
and stimulated with either 1 mM adenosine or 1 mM AMP. Cells were pre-incubated with
10 μM αβ-met-ADP for 3 min, which was maintained throughout the experiment.
Adenosine (1 mM) response was assessed in the presence of 100 μM pCPT-cAMP, 5 μM
BABPA, or 500 μM pCPT-cGMP. AUC measurements were obtained for 1 min from
agonist addition. All experiments were performed in triplicate. (D) pCPT-cGMP dose-
dependently inhibited 5′-AMP hydrolysis by secretory hPAP (black) and mPAP (red),
respectively, at pH 7.0. Inorganic phosphate was detected using malachite green. The
structure and IC50 values are shown (insets). All experiments were performed in triplicate.
n=22–77 cells per condition. All data are presented as mean ± s.e.m.
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